Background {#Sec1}
==========

Drug--drug interactions (DDIs) are a growing concern in all clinical settings, particularly intensive care units (ICUs) \[[@CR1]\]. ICU-admitted patients are at an increased risk of DDIs due to the complexity of pharmacotherapy, large number of medications, disease severity, and organ failure \[[@CR2]--[@CR5]\]. DDIs are common causes of adverse drug events that may affect patient health; therefore, the identification and prevention of potential drug--drug interactions (pDDIs) could improve patient safety \[[@CR6]\]. Since it would be impossible for any physician to remember all pDDIs, improving the knowledge of clinical practitioners in terms of clinically important DDIs could reduce the risk of serious adverse outcomes. Applying DDI software and employing clinical pharmacists to detect and prevent DDIs have improved patient safety in advanced countries \[[@CR1], [@CR7]\], while physicians in developing countries still identify DDIs based on their own experiences \[[@CR8], [@CR9]\].

Previous studies regarding pDDIs have focused on frequency, type, mechanisms, severity, drug combinations, management and related outcomes in ICU settings \[[@CR1], [@CR10]--[@CR14]\], but important drug classes involved in well-documented and severe pDDIs in cardiothoracic ICU have not yet been reported. Therefore, the current study aimed to highlight the main drug classes associated with clinically important DDIs. The results of this study could increase knowledge among intensivists (especially cardiothoracic intensivists) in the context of DDI prevention and safe medication usage.

Methods {#Sec2}
=======

Study design and protocol {#Sec3}
-------------------------

This cross-sectional study was conducted at Masih Daneshvari Hospital, a university-affiliated hospital for lung diseases, over a 6-month period. The study protocol was approved by the hospital's ethical review board. Data related to the pharmacotherapy of the subjects were assessed 48 h after admission to an 8-bed surgical cardiothoracic ICU by a clinical pharmacologist using Lexi-Interact database, a complete drug and herbal interaction analysis program. The software identifies interacting drugs, mechanisms, severity, reliability (documentation) rating (E = excellent, G = good, F = fair), potential outcomes, and clinical management. According to severity, the interactions are categorized into five categories: A (unknown), B (minor), C (moderate), D (major), and X (contraindicated) \[[@CR15]\]. Drugs involved in pDDIs and subjects' diagnoses were classified according to AHFS Drug Information \[[@CR16]\] and International Classification of Diseases (ICD10), respectively \[[@CR17]\]. At the time of admission, any home medication, herbal medication, and nutritional supplements were stopped according to the ICU policy. Hydro-electrolytic components, insulin, water-soluble vitamins, and topical drugs were excluded from further analysis. Physicians were notified of interactions that might lead to alterations in drug therapy.

Data analysis {#Sec4}
-------------

Data were analyzed using descriptive statistics from the SPSS software v.22.0 for Windows (SPSS, Chicago, IL). The median, range, and percentage were applied to present the results where appropriate. The interacting drug classes, significance, reliability, and clinical management of the interactions were recorded in a database. Interactions with a severity rating of D and/or X and a reliability rating of E and/or G were considered clinically important pDDIs for more analysis.

Results {#Sec5}
=======

Overall, 195 prescriptions were evaluated over the 6-month study period. Table [1](#Tab1){ref-type="table"} shows the demographic and clinical characteristics of the subjects. The average length of stay in ICU was 5 days. Total administered and interacting medications (D and X interactions with any documentation rating) were 1780 and 496, respectively (Table [2](#Tab2){ref-type="table"}). D and/or X interactions were identified in 37.94 % (74) of the prescriptions. Of the 248 pDDIs with a severity rating of D and/or X, 157 were unique drug pairs (a specific combination of interacting medication that is counted one time). The drug classes and specific medications involved in D and/or X interactions are shown in Table [3](#Tab3){ref-type="table"}. The drug pairs causing D and/or X interactions with E and/or G reliability are displayed in Table [4](#Tab4){ref-type="table"}.Table 1Demographic and clinical characteristics of the patientsCharacteristicsNumber of patients (*n*)184Age \[median (range)\]48 (3--85)Gender (male/female)110/74Number of prescriptions (*n*)195Number of prescriptions including: 1--8 drugs (*n*)110 9--17 drugs (*n*)71 18--25 drugs (*n*)14Diagnoses classification (*n*) Certain infectious and parasitic diseases7 Neoplasms43 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism1 Diseases of the circulatory system32 Diseases of the respiratory system68 Diseases of the digestive system6 Congenital malformations, deformations and chromosomal abnormalities6 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified1 Injury, poisoning and certain other consequences of external causes4 Factors influencing health status and contact with health services16Table 2The number and percentages of total administered and interacting drugs in different drug classesDrug classesTotal administered drugs % (*n*)D and/or X interacting drugs % (*n*)D and/or X interacting precipitant drugs with E and/or G reliability % (*n*)Anti-infective agents22.35 % (398)25.00 % (124)45.87 % (50)Central nervous system agents20.50 % (365)19.95 % (99)14.67 % (16)Cardiovascular drugs19.21 % (342)13.10 % (65)5.50 % (6)Gastrointestinal drugs12.80 % (228)6.65 % (33)4.58 % (5)Hormones and synthetic substitutes6.68 % (119)11.29 % (56)2.75 % (3)Respiratory tract agents6.40 % (114)3.22 % (16)--Electrolytic, caloric, and water balance5.33 % (95)6.65 % (33)10.09 (11)Blood formation, coagulation, and thrombosis2.07 % (37)3.42 % (17)3.67 % (4)Autonomic drugs2.02 % (36)3.02 % (15)9.17 % (10)Miscellaneous therapeutic agents2.02 % (36)7.05 % (35)3.66 % (4)Vitamins0.56 % (10)0.60 % (3)--Total1780496109Table 3Drug classes, specific medications associated with D and/or X interactions, and the frequency of interactionsDrug classes (frequency of interactions)Specific medications (frequency of interactions)Anti-infective agents (124)Itraconazole (24), Ciprofloxacin (17), Voriconazole (16), Rifampin (14), Clarithromycin (11), Erythromycin (10), Dapsone (7), Co-trimoxazole (5), Levofloxacin (4), Posaconazole (4), Meropenem (3), Ofloxacin (3), Isoniazid (2), Pyrazinamide (1), Lamivudine (1), Valganciclovir (1), Caspofungin (1)Central nervous system agents (99)Carbamazepine (20), Phenytoin (16), Fentanyl (11), Midazolam (10), Haloperidol (8), Valproic acid (5), Indomethacin (5), Quetiapine fumarate (4), Citalopram (4), Risperidone (2), Imipramine (2), Clonazepam (2), Methadone (2), Lorazepam (1), Chlorpromazine (1), Celecoxib (1), Diclofenac (1), Fluvoxamine (1), Alprazolam (1), Clomipramine (1), Carbidopa and Levodopa (1)Cardiovascular drugs (65)Atorvastatin (19), Metoprolol (10), Losartan (6), Amiodarone (6), Amlodipine (4), Diltiazem (4), Captopril (3), Sildenafil (2), Carvedilol (2), Furosemide (2), Digoxin (2), Propranolol (1), Dabigatran (1), Heparin (1), Enalapril (1), Gemfibrozil (1)Hormones and synthetic substitutes (56)Dexamethasone (33), Prednisolone (9), Methylprednisolone (6), Levothyroxine (4), Hydrocortisone (3), Octreotide (1)Miscellaneous therapeutic agents (35)Cyclosporine (15), Tacrolimus (10), Mycophenolate (6), Tamsulosin (3), ALLOPURINOL (1)Electrolytic, caloric, and water balance (33)Calcium carbonate (16), Magnesium sulfate (5), Sodium polystyrene sulfate (4), Calcium gluconate (3), Sodium phosphate (2), Spironolactone (1), Zinc sulfate (1), Potassium chloride (1)Gastrointestinal drugs (33)Pantoprazole (19), Granisetron (8), Ranitidine (3), Metoclopramide (1), Omeprazole (1), Aluminum, Magnesium hydroxide (1)Blood formation, coagulation, and thrombosis (17)Warfarin (6), Clopidogrel (4), Ferrous sulfate (4), Acetylsalicylic acid (3)Respiratory tract agents (16)Ipratropium (7), Formoterol (3), Fluticasone (3), Salbutamol (2), Theophylline (1)Autonomic drugs (15)Atracurium (9), Tizanidine (2), Prazosin (2), Cisatracurium (1), Epinephrine (1)Vitamins (3)Calcitriol (3)Table 4Drug classes, precipitant and object drugs, mechanisms and recommendations for clinically significant pDDIsDrug classesPrecipitant drugs^a^Object drugs^a^MechanismsRecommendationsAnti-infective agentsItraconazoleTacrolimusMetabolism (inh)Monitor tacrolimus concentrationDiltiazemMetabolism (inh)Monitor diltiazem toxic effectsDigoxinAbsorptionMonitor digoxin concentrationAtorvastatinMetabolism (inh)Reduce dose, monitor toxic effectsClarithromycinMetabolism (inh)^b^Monitor toxic effect of clarithromycin/itraconazoleMethylprednisoloneMetabolism (inh)Reduce dose, monitor corticosteroid toxicityVoriconazoleTacrolimusMetabolism (inh)Reduce dose, monitor tacrolimus concentrationCyclosporineMetabolism (inh)Reduce dose, monitor cyclosporine concentrationDiltiazemMetabolism (inh)Monitor diltiazem toxic effectsMethylprednisoloneMetabolism (inh)Reduce dose, monitor corticosteroid toxicityMethadoneMetabolism (inh)Monitor methadone toxic effectsMidazolamMetabolism (inh)Monitor midazolam toxic effectsCiprofloxacinTheophyllineMetabolism (inh)Reduce dose, monitor theophylline toxic effectsErythromycinAdditiveAvoid combinationFormoterolAdditiveAvoid combinationGranisetronAdditiveAvoid combinationVoriconazoleAdditiveAvoid combinationRifampinItraconazoleMetabolism (ind/inh)^b^Avoid combination/monitor for clinical response to itraconazoleClarithromycinMetabolism (ind/inh)^b^Monitor for clarithromycin therapeutic effects/rifampin toxic effectsCyclosporineMetabolism (ind)Consider an alternative, monitor cyclosporine serum concentrationsMidazolamMetabolism (ind)Monitor midazolam therapeutic effectsDapsoneMetabolism (ind)Monitor for dapsone therapeutic effects and methemoglobinemiaErythromycinAmlodipineMetabolism (inh)Consider an alternative, monitor toxic effectsCarbamazepineMetabolism (inh)Consider an alternative, monitor toxic effectsDexamethasoneMetabolism (inh)Monitor corticosteroids toxic effectsPrednisoloneMetabolism (inh)Monitor corticosteroids toxic effectsPosaconazoleMidazolamMetabolism (inh)Consider an alternative, monitor toxic effectsIsoniazidMetoprololMetabolism (inh)Consider an alternative, monitor responseValganciclovirLamivudineAdditiveMonitor hematologic toxicityClarithromycinMidazolamMetabolism (inh)Consider an alternative, monitor for toxic effectsCentral nervous system agentsCarbamazepinePhenytoinMetabolism (ind)^b^Monitor for phenytoin/carbamazepine serum concentrationsClonazepamMetabolism (ind)Consider an alternativeWarfarinMetabolism (ind)Monitor therapeutic effectsCitalopramMetabolism (ind/inh)^b^Monitor citalopram therapeutic effects/carbamazepine toxic effectsFluvoxamineMetabolism (ind/inh)^b^Monitor fluvoxamine therapeutic effects/carbamazepine toxic effectsImipramineMetoprololMetabolism (inh)Consider an alternative, monitor responseCitalopramMetabolism (inh)^b^Consider an alternative, monitor toxic effects of imipramine/citalopramQuetiapine fumarateHaloperidolAdditiveAvoid combinationCarbidopa and levodopaAntagonisticConsider an alternativePhenytoinAmlodipineMetabolism (ind/inh)^b^Monitor amlodipine therapeutic effects/phenytoin toxicityIndomethacinAcetylsalicylic acidAdditiveMonitor bleeding, avoid regular use of indomethacinCyclosporineAdditiveConsider an alternative, monitor nephrotoxicityFurosemideAntagonisticMonitor therapeutic effectValproic acidLorazpamMetabolism (inh)Monitor lorazepam toxic effectsElectrolytic, caloric, and water balanceSodium polystyrene sulfateCalcium carbonateAntagonisticSeparate doses by 2 or more hours, monitor metabolic alkalosisZinc sulfateOfloxacinAbsorptionSeparate doses by 2 or more hoursMagnesium sulfateCiprofloxacinAbsorptionSeparate doses by 2 or more hoursCalcium carbonateIsoniazidAbsorptionSeparate doses by 2 or more hoursLevofloxacinAbsorptionSeparate doses by 2 or more hoursMycophenolateAbsorptionSeparate doses by 2 or more hoursAutonomic drugsAtracuriumMethylprednisoloneAdditiveMonitor neuromuscular adverse effectsPrednisoloneAdditiveMonitor neuromuscular adverse effectsDexamethasoneAdditiveMonitor neuromuscular adverse effectsHydrocortisoneAdditiveMonitor neuromuscular adverse effectsCisatracuriumPrednisoloneAdditiveMonitor neuromuscular adverse effectsCardiovascular drugsAmiodaroneDigoxinExcretionReduce digoxin dosage, monitor serum concentrationMetoprololMetabolism (inh)Consider an alternative, monitor responseGemfibrozilAtorvastatinMetabolism (inh)Avoid combinationMetoprololEpinephrineAdditiveMonitor pressor effects of epinephrineBlood formation, coagulation, ......Acetylsalicylic acidWarfarinAdditiveMonitor bleedingFerrous sulfateOfloxacinAbsorptionSeparate doses by 4 or more hoursLevothyroxineAbsorptionSeparate doses by 2 or more hoursGastrointestinal drugsPantoprazoleItraconazoleAbsorptionAdminister itraconazole with an acidic beverage, monitor responseRanitidineItraconazoleAbsorptionAdminister itraconazole with an acidic beverage, monitor responseHormones and synthetic substitutesDexamethasoneClarithromycinMetabolism (ind/inh)^b^Consider alternative antimicrobial therapy/monitor for dexamethasone toxic effectsItraconazoleMetabolism (ind)Avoid combination, monitor for therapeutic effectsMiscellaneousCyclosporineAtorvastatinMetabolism (inh)Avoid combinationMycophenolateExcretionMonitor mycophenolate dosing and response to therapy*inh* Inhibition, *ind* induction^a^The precipitant drug causes the interaction and the object drug is affected by the interaction^b^Both medications act on each other

Discussion {#Sec6}
==========

The present study evaluated clinically important pDDIs in terms of drug classes, mechanisms, and recommendations in the cardiothoracic ICU. Scientifically, important measures to decrease the risk of DDIs are computerized prescribing, pharmacotherapy monitoring, and pharmacist participation in the multidisciplinary team \[[@CR18]\]. Where these services are not available (e.g., due to budget shortages), continued education and expert studies on pDDIs could improve patient safety. Software that identifies a large number of DDIs with any rating of severity and reliability could result in a lack of attention given to the warnings \[[@CR19]\]. Categorizing DDIs by drug classes and highlighting more severe and reliable interactions may increase the tendency of clinicians to prevent clinically significant DDIs.

Results of the current study revealed that anti-infective, central nervous system (CNS), and cardiovascular agents were the main drug classes involved in D and X pDDIs. Antimicrobials were the most administered medications in the studied setting and were responsible for a high number of pDDIs. Anti-infective agents are commonly used in the ICU and are associated with clinically significant interactions \[[@CR20]\]. Antithrombotic agents and cardiovascular drugs are usually reported as the most common interacting drug groups in ICU settings \[[@CR1], [@CR10]--[@CR12]\]. Different results may be related to the inclusion of moderate and/or not well-documented pDDIs in other studies. These authors' previous study also showed that antibiotics were the most commonly implicated drug class for adverse drug reactions \[[@CR21]\]. Overestimated usage of antibiotics is an important issue in developing countries where the use of antibiotics requires close monitoring to ensure effective treatment and, ultimately, cost reduction \[[@CR22]\].

A wide range of different consequences could be predicted according to DDIs mechanisms. The altered gastrointestinal (GI) absorption of antibiotics and the inhibition/induction of drug metabolizer enzymes are the mechanisms most often associated with antimicrobial interactions \[[@CR20], [@CR23]\]. The inhibition of metabolism by azole antifungal agents (most interacting drugs in the current study) may lead to increased tacrolimus and cyclosporine concentrations in transplant patients and the increased toxicity of these medications \[[@CR24]\]. On the other hand, metabolism induction usually results in decreased clinical efficacy of other drugs instead of adverse effects. Quinolones and macrolides (with torsadogenic potential) may interact synergically with other medications and result in QTc prolongation and torsades de pointes \[[@CR25]\]. It was also found that these mechanisms play the main role in anti-infective interactions that could be managed by adjusting drug administration time, and dosage, or using an alternative medication \[[@CR23], [@CR25]\].

CNS drugs were 20.50 and 19.95 % of administered medications and interacting drugs, respectively. These medications are frequently used to control seizures, pain, and anxiety and to treat delirium, depression, and psychotic symptoms in ICU settings \[[@CR26]\]. A conducted study in a mixed ICU showed that 40 % of the pDDIs were associated to drugs acting on CNS \[[@CR27]\]. In the current study, 14.67 % of D and/or X pDDIs with reliability ratings of E and/or G were related to these agents as a precipitant drug. Carbamazepine was the most frequent CNS drug that interacted with CYP3A substrates (such as phenytoin, clonazepam, and warfarin). Monitoring the therapeutic effects of object drugs and considering an alternative medication (if possible) are recommended as appropriate interventions \[[@CR28]\]. In addition to metabolism, additive and antagonistic effects were the main mechanisms for CNS drug interactions in this study.

Electrolytic, caloric, and water balance agents, which include metal ions, accounted for 10.09 % of clinically important pDDIs. Metal ions form complexes with other medications, especially antimicrobial agents, and affect drug absorption. A reasonable recommendation is to administer oral medications at least 1--2 h before, and not within 4 h after, administering the metal ions \[[@CR23]\].

In autonomic drug classes, the combination of neuromuscular blocking agents and corticosteroids may lead to further risk of prolonged muscle weakness, including neuropathy, myopathy, and/or paralysis. This has been observed most commonly in the ICU setting, particularly in patients requiring high doses of intravenous steroids \[[@CR29]\]. It is recommended to monitor for new onset or worsening of adverse neuromuscular effects and to use a neuromuscular blocking drug only when absolutely necessary \[[@CR30]\]. Corticosteroids were administered commonly for tracheal stenosis (15.2 %) and COPD (4.3 %) in the studied setting. After that, neoplasms (23.4 %) and transplants (8.7 %) were the most common indications for corticosteroid administrations.

Although "cardiovascular" and "blood formation, coagulation, and thrombosis" agents accounted for 21.28 % of administered medications and 16.52 % of interacting drugs, only 9.17 % of well-documented D and/or X interactions were related to these groups as precipitant drugs. As mentioned above, pDDIs were classified according to the object and precipitant drugs. In 18.35 % of pDDIs, the drugs belonging to these groups were object drugs. Documentation rating was considered to highlight clinically important pDDIs. A high number of interactions caused by these drug classes were rated as fair documentation. Amiodarone (a CYP2D6 inhibitor) should be considered as a precipitant drug with a large number of interactions. Considering an alternative for one of the interacting agents and monitoring responses are usually recommended \[[@CR31]\].

Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H~2~RAs) are routinely used for critically ill subjects who are at high risk for stress-related mucosal damage (SRMD) \[[@CR32]\]. The pH-raising effect of these GI drugs may decrease absorption and the serum concentration of azole antifungal agents (itraconazole, voriconazole, and posaconazole). Use of the azoles oral solutions (instead of capsule) or administration of the azoles with an acidic beverage could minimize the significance of this interaction \[[@CR33]\]. Variations in practices and medications between ICU settings may lead to different pDDIs patterns \[[@CR1]\]. Proton pump inhibitors are administered in the currently studied setting to patients with a history of GI disorders, major surgeries, and anticoagulant usage. Although there is lack of firm evidence that PPI reduces GI bleeding compared with H2RA or placebo in ICU patients \[[@CR34]\], an international survey of 97 units in 11 countries showed that PPIs were the most common stress ulcer prophylaxis agent, used in 66 % of ICUs (64/97) \[[@CR35]\]. Using oral PPIs instead of intravenous injection could be a useful strategy to prevent pDDIs.

In hormone and synthetic substitutes, an important interaction occurred between dexamethasone and CYP3A substrates (clarithromycin and itraconazole). Dexamethasone as a strong CYP3A inducer may decrease the serum concentration and therapeutic effectiveness of these medications \[[@CR36]\]. Alternative antimicrobial therapy (when possible) and monitoring patients closely for evidence of diminished clinical response are important preventive measures.

Immunosuppressive drugs classified as miscellaneous therapeutic agents can lead to life-threatening pDDIs in transplant subjects. Cyclosporine has been shown to reduce the AUC of mycophenolic acid (MPA) by inhibiting its glucuronide conjugate mycophenolic acid glucuronide conjugate (MPAG) excretion into the bile. Changes in mycophenolate dosage may be required in cases of concurrent cyclosporine starting, stopping, or dose changing \[[@CR37]\]. Studies have shown that the concurrent use of cyclosporine with atorvastatin can increase systemic exposure to the statins and related toxicities such as myopathy and rhabdomyolysis. A statin that is less sensitive to this interaction (e.g., pravastatin or fluvastatin) or an alternative type of LDL-lowering medication should be considered \[[@CR37], [@CR38]\].

Several limitations could be considered for the current study. Age is an important factor for DDIs prevalence, and a positive relationship has been found between age and the number of DDIs \[[@CR9]\]. The median age of patients in this study (48 years) was lower than that of western countries. Differences between the ICUs in developing and advanced countries could explain this discrepancy. For an appropriate interpretation and application of the ICU data, the diversity among countries including funding, laws, cultural values, and disease prevalence should be considered \[[@CR39], [@CR40]\]. In the current study, tracheal stenosis and empyema were the most common respiratory system diseases that lead to ICU admissions. Therefore, several reasons (prevalence of diseases, culture, laws, and life expectancy) may play a role in the low median age of patients in the current study.

The second limitation is using one DDI database that could limit the number of pDDIs. Lexi-Interact is a commonly used resource providing detailed DDI information and was available in the studied hospital. This database with a documentation rating that is useful in recognizing well-documented interactions would limit clinical repercussions. Using different software at the same time, however, could lead to more accurate results \[[@CR41]\]. The setting of the current study, the cardiothoracic ICU of a pulmonary referral hospital, is another limitation. A list of drugs approved by hospital formulary committee is specific for an ICU setting. However, commonly used drugs in ICUs are usually considered in critical care drug handbooks and manuals \[[@CR42], [@CR43]\]. Therefore, reported interactions related to common drugs could be generalized to other ICUs. The interactions caused by specific medications prescribed in a specialized ICU could also be identified and prevented by similar studies.

Conclusions {#Sec7}
===========

Due to the high prevalence of pDDIs in the ICU setting, the authors recommend more specialized studies on clinically significant pDDIs and continued education based on the results. Highlighting important drug classes and specific medications responsible for the interactions in different settings could increase the knowledge and awareness of clinicians to improve patient safety.
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